Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06349668 2026-02-05

SMILe

Phase 3 Recruiting

220 enrolled

Genitourinary

Kidney Neoplasms, Ureteral Neoplasms, Vesico-Ureteral Reflux, Nephrolithiasis

NCT06465069 2026-01-22

NEXUS-01

Phase 1 Recruiting

420 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Phase 3 Completed

608 enrolled 22 charts 1 FDA

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT01352962 2026-01-05

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Phase 1 Completed

18 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT07087860 2025-12-09

RECIPE-B1

Phase 2 Recruiting

70 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03288545 2025-11-10

EV-103

Phase 1/2 Active not recruiting

348 enrolled 1 FDA

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT00479128 2025-10-28

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Phase 1 Active not recruiting

80 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT07125547 2025-08-15

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

Phase 2 Recruiting

35 enrolled

Ureteral Neoplasms

NCT06983210 2025-08-14

GRAPE

Phase 2 Recruiting

43 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Phase 2 Recruiting

25 enrolled

Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

Phase 1/2 Withdrawn

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

Phase 2 Terminated

32 enrolled 14 charts

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Clinical Trials

AMBASSADOR

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

COAXIN

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

EXCEED

SMILe

NEXUS-01

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

RECIPE-B1

EV-103

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

GRAPE

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

Afatinib in Advanced Refractory Urothelial Cancer